Editas Medicine (EDIT) Stock Price
$1.39 4.5%
to add to portfolio
AI Score
-
Alternative
5 -
Fundamental
1 -
Technical
3
Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.
Sign up to get access to more historical data and insights on Editas Medicine, AI stock picks, stock alerts and much more.
EDIT AI Stock Analysis
AI stock analysis for EDIT is missing at the moment.
Our AI stock analysis reviews financial data, technical analysis, and alternative data insights to project stock performance. For example, analyzing a company like Editas Medicine (EDIT) provides a clear summary of future projections. Gain the edge you need to make confident, data-driven investment decisions.
Sign up and become a member to get access to AI stock analysis.
Sign up
Editas Medicine (EDIT) Price Prediction
Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Editas Medicine (EDIT), currently trading at $1.39, will... Sign up to access price prediction.
Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.
About EDIT
-
Editas Medicine, Inc.
-
Symbol
EDIT
-
Market
NASDAQ
-
Industry
Biotechnology
-
Market Cap
116.4M
Similar Stocks
 |
Catalyst Pharmaceuticals CPRX |
$22.76 3% |
5 |
 |
Inovio Pharmaceuticals INO |
$1.82 3.4% |
1 |
 |
Moderna MRNA |
$24.38 1.3% |
3 |
 |
Anavex Life Sciences AVXL |
$8.56 0.9% |
4 |
 |
BridgeBio Pharma BBIO |
$34.83 2.8% |
4 |
News
EDIT Alternative Data
Web Traffic
Editas Medicine receives an estimated 22842 monthly visitors to editasmedicine.com.
-
Web Traffic
22842
-
Change from Previous Month
4%
-
3 Month Change
30.7%
-
YoY Change
30.7%
LinkedIn Followers
48,517 are following Editas Medicine on LinkedIn, up by 0.5% over the last month.
-
LinkedIn Followers
48517
-
Daily Change
0%
-
1 Month Change
0.5%
-
3 Month Change
2.2%
Job Postings
Editas Medicine has an estimated 0 open job postings, which is down -100% over the last month.
-
Job Postings
0
-
Daily Change
0%
-
1 Month Change
100%
-
3 Month Change
100%
-
YoY Change
100%
LinkedIn Employees
According to LinkedIn, Editas Medicine has 271 employees, down by -14.5% over the last month.
-
LinkedIn Employees
271
-
Daily Change
0%
-
1 Month Change
14.5%
-
3 Month Change
16.1%
-
YoY Change
16.1%
Reddit Mentions
Editas Medicine has been mentioned an estimated 0 times in investment subreddits on Reddit over the last 24 hours.
-
Reddit Mentions
0
-
Daily Change
0%
-
1 Month Change
100%
-
3 Month Change
0%
News Mentions
Editas Medicine was mentioned 0 times in the news yesterday.
-
News Mentions
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
Business Outlook
According to employee reviews, the business outlook among employees at Editas Medicine is 52 out of 100 (neutral).
-
Business Outlook
52
-
Change from Previous Month
0%
-
3 Month Change
0%
-
YoY Change
0%
EDIT Financials
EDIT Key Metrics
-
Total Revenue
$30.6M
-
Net Income
-$45.4M
-
Earnings per Share
-$0.55
-
Free cash flow
-$51.3M
-
EBITDA
-$33M
-
EBITDA Ratio
-1.07764
-
Total Assets
$341.6M
EDIT 2-year Revenue & Income
EDIT 2-year Free Cash Flow
EDIT Technicals
EDIT SMA
EDIT RSI
FAQ
What's the current price of Editas Medicine (EDIT) Stock?
The price of an Editas Medicine (EDIT) share is $1.39.
What's the market cap of Editas Medicine?
The current market cap of Editas Medicine is 116.4M.
Should I buy or sell EDIT?
Editas Medicine exhibits several negative alternative data signals, leading us to expect continued underperformance in the coming months. As a result, we maintain a negative outlook on this stock.
Is Editas Medicine a good investment?
Considering the fundamentals, technical analysis, and alternative data insights, it may not be the best time to invest in Editas Medicine stock. There are several bearish signals and market challenges that could negatively impact Editas Medicine's future performance, suggesting that caution should be exercised before making any investment decisions.
Is now a good time to buy Editas Medicine (EDIT) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, it may not be the best time to buy Editas Medicine stock right now, as the outlook appears bearish.
What are some stocks similar to Editas Medicine (EDIT) that investors often compare it to?
Editas Medicine (EDIT) is often compared to similar stocks such as Catalyst Pharmaceuticals, Inovio Pharmaceuticals, Moderna, Anavex Life Sciences and BridgeBio Pharma.
What is the forecast for Editas Medicine's stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Editas Medicine's stock price to be around $1.27 in 2026. Starting from the current price of $1.39, this represents a 8.7% change in price, indicating a bearish outlook for the stock.
How to buy Editas Medicine (EDIT) Stock?
Editas Medicine stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Editas Medicine shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.